Rafael Amado is Senior Vice President, Oncology R&D at GlaxoSmithKline. He is accountable for integrating oncology R&D efforts from drug target identification through late-stage development and registration globally.
Rafael joined GSK in 2008 as Vice President, Medicine Development Leader for Votrient. In that capacity he was responsible for developing and executing the asset’s development strategy globally. He served in positions of increasing responsibility as Vice President, Oncology Solid Tumors and Senior Vice President, Oncology Development, to his current role of head of Oncology R&D. During his tenure, he has overseen the development and registration of indications globally of multiple products including Votrient, Tykerb/Tyverb, Promacta/Revolade, Arzerra, Mekinist, and Tafinlar, and has led the development of a pipeline of products in novel areas of cancer biology.
Prior to joining GSK, Rafael was Executive Director in the Therapeutic Oncology Area at Amgen where he was responsible for development activities of several assets, including global registration for Vectibix. An area of his interest is biological characterization of tumors for patient selection, which he successfully applied to targeted drug development with EGFR inhibitors in colorectal cancer. Rafael trained as a Hematologist/Oncologist at the University of California, Los Angeles, where he remained as faculty until joining Amgen in 2003.
A native of Spain, he holds an M.D. from the University of Seville School of Medicine. He performed his residency in Internal Medicine at Michael Reese Hospital, a University of Chicago Affiliated Hospital, and his fellowship in Hematology/Oncology at the University of California, Los Angeles. He has published extensively in his field, and is a member of multiple professional societies.